Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts

Assiut University

Status and phase: Completed; Phase 4

Conditions: Plantar Wart; Common Wart

Treatments: Procedure: cryotherapy; Drug: Measles-Mumps-Rubella Vaccine

Study type: Interventional

Funder types: Other

Identifiers

NCT03183765

MMRVCRYO

Details and patient eligibility

About

Warts are benign epidermal tumors caused by human papilloma virus, which are epitheliotropic non-enveloped double stranded DNA viruses. Transmission of warts occurs from direct person-to-person contact or indirectly by fomites . Warts appear in various forms including verruca vulgaris, plane, plantar, filiform, digitate and periungual.

Full description

Treatment of warts is difficult for patients and physicians . Currently Available treatment options include cryosurgery, laser, electrosurgery, bleomycin, and topical keratolytic applications; many of them are painful, ineffective, costly and prone for recurrences.

Cryotherapy, which uses liquid nitrogen to freeze tissues and destroy warts, is one of the most common and effective treatments. freezing causes local irritation, leading the host to mount an immune reaction against the virus.

Immunotherapy appears to enhance virus recognition by immune system; allowing clearance of treated wart, distant warts , and helps to prevent infection .Recently, intralesional immunotherapy using different antigens such as mumps, Candida, and tuberculin has been proved effective in the treatment of warts.

The exact mechanism of action of intralesional immunotherapy is still obscure. Intralesional antigen injection probably induces strong non specific inflammatory response against the human papilloma virus-infected cells.

It has been suggested that intralesional measles mumps rubella vaccine results in regression of warts via induction of immune system.

Enrollment: 48 patients

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients should have multiple common or plantar warts.
• No concurrent systemic or topical treatment of warts

Exclusion criteria

• patients under 16 years old.

  • Patients with fever or signs of any inflammation or infection.

• Patients with other types of warts.

• Patients with single warts.

  • Pregnancy.
  • Lactation.
  • Immunosuppression.
  • Patients who received any other treatments for their warts in the month before starting study.
  • Past history of asthma, allergic skin disorders, meningitis or convulsions.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

48 participants in 2 patient groups

MMR vaccine

Experimental group

Description:

Measles-Mumps-Rubella Vaccine will be injected 0.5 ml into the largest wart at 2-week intervals until complete clearance was achieved or for a maximum of 3 treatments

Treatment:

Drug: Measles-Mumps-Rubella Vaccine

Cryotherapy

Active Comparator group

Description:

patients received cryotherapy with liquid nitrogen once every 2 weeks until complete clearance or for a maximum of 3 sessions

Treatment:

Procedure: cryotherapy